

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re:	Chaudry	Confirmation No.:	8210
Appl. No.:	10/609,233	Group Art Unit:	1616
Filed:	June 27, 2003	Examiner:	Haghighatian, M.
For:	INHALABLE FORMULATIONS FOR TREATING PULMONARY HYPERTENSION AND METHOD OF USING SAME		

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT  
UNDER 37 C.F.R. § 1.97(c)**

Sir:

This Information Disclosure Statement is being filed after a Final Office Action under 37 C.F.R. § 1.113 or a Notice of Allowance under 37 C.F.R. § 1.311, but before payment of the Issue Fee. The Final Office Action or Notice of Allowance was mailed on October 17, 2006.

Attached is a list of documents on form PTO-1449 along with any cited foreign patent documents and non-patent literature documents in accordance with 37 CFR 1.98(a)(2).

By identifying the listed documents, Applicant in no way makes any admission as to the prior art status of the listed documents, but is instead identifying the listed documents for the sake of full disclosure.

In accordance with the requirements of 37 C.F.R. § 1.97(d)(2), the following statement as specified in 37 C.F.R. § 1.97(e) is made:

No item of information contained in this statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge the person signing this document after making reasonable inquiry, no item of information contained in this statement was known to any individual designated in 37 C.F.R. § 1.56(c) more than three (3) months prior to the filing of this statement.

In re: Chaudry  
Appl. No.: 10/609,233  
Filed: June 27, 2003  
Page 2

---

Please charge Deposit Acct. No. 16-0605 for the \$180.00 fee specified in 37 C.F.R.  
§ 1.17(p). The Commissioner is authorized to charge any additional fee, or credit any refund, to  
our Deposit Account No. 16-0605.

Respectfully submitted,



John E. Johnson, III  
Registration No. 58,367

**CUSTOMER NO. 00826**  
**ALSTON & BIRD LLP**  
Bank of America Plaza  
101 South Tryon Street, Suite 4000  
Charlotte, NC 28280-4000  
Tel Charlotte Office (704) 444-1000  
Fax Charlotte Office (704) 444-1111

**ELECTRONICALLY FILED USING THE EFS-WEB ELECTRONIC FILING SYSTEM OF THE UNITED STATES PATENT & TRADEMARK OFFICE ON April 17, 2007.**

Substitute for form 1449/PTO (Revised 07/2005)				<b>Complete if Known</b>	
				<b>Application Number</b>	10/609,233
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Filing Date</b>	June 27, 2003
				<b>First Named Inventor</b>	Chaudry
				<b>Group Art Unit</b>	1616
				<b>Examiner Name</b>	Mina Haghighatian
				<b>Attorney Docket Number</b>	048765/277090
<b>Sheet</b>	1	<b>of</b>	1		

[illegible]

Examiner Initials	Cite No.	<u>Foreign Patent Document</u> Country Code - Number Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	English Language Translation Attached

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s) , volume/issue number(s), publisher, city and/or country where published.	English Language Translation Attached
	5	<i>Inhalation of Nebulized Nitroglycerin in Dogs with Experimental Pulmonary Hypertension Induced by U46619</i> , F. Gong et al., <i>Pediatrics International</i> (2000) 42, pp. 225-258	
	6	<i>Effects of Aerosolised Substance P on Lung Resistance in Guinea-Pigs: A Comparison Between Inhibition of Neutral Endopeptidase and Angiotensin-Converting Enzyme</i> , J. O. Lotvall et al., <i>Br. J. Pharmacol</i> , 1990, 100, pp. 69-72	
Examiner Signature	Date Considered		

Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LEGAL-02/30297117v1